EMA’s objectives all focus on the same object: improvement of the medical profession in the European context.
- To act in order to influence Health policies according to practising doctors’ priorities
- To form a forum of doctors working in the European Union’s medical community
- To provide its members with information and services that facilitate their professional activity
- To contribute to the improvement of healthcare given to patients by helping its members keep abreast of latest the developments
- To influence the development of health care in Europe by defending its members’ opinions
These objectives are ambitious, yet realistic.
EMA has been active on many different projects in the scope of its activities, you are invited to discover them in the “Projects” section of this web site. EMA also offers a range of “Information & Services” aimed at health professionals that are also available on this web site. Use the navigation menu to explore them.
Proof of your qualifications
To work as a doctor in another EU country, you must apply to the authority that oversees the doctor profession in that country, providing proof of your qualifications. The authority must:
- acknowledge your application within 1 month of receiving it, and ask you missing but necessary documents to process the application
- assess your qualifications and decide whether to grant your application within 3 months (or 4 months for certain complicated cases in the area of non automatic recognition)
Rose of Paracelsus
The medal of Paracelsus and the Rose of Paracelsus, are two awards established by EMA in cooperation with EBA
The Paracelsus medal is intended to reward physicians with at least 25 years of professional activity, and who meet the meet the following criteria
- To be Medical Doctor
- At least 25 years of professional activity,
- Recent clean criminal record
The Rose of Paracelsus is an award that is given to those who have excelled in the field of public health, in the organization, implementation and modernization of care and health services in general.
Everyone who has been given this recognition, will be incorporated in an official register kept in the archives of EMA and published on our sites.
If you are interrested, please register as full membership.
For full active members, please click here under to proceed to the solicitation form
The EU Framework Programme for Research and Innovation
Horizon 2020 is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020) -in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.
Horizon 2020 is the financial instrument implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe’s global competitiveness. Seen as a means to drive economic growth and create jobs, Horizon 2020 has the political backing of Europe s leaders and the Members of the European Parliament. They agreed that research is an investment in our future and so put it at the heart of the EU s blueprint for smart, sustainable and inclusive growth and jobs.
By coupling research and innovation, Horizon 2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation. Horizon 2020 is open to everyone, with a simple structure that reduces red tape and time so participants can focus on what is really important. This approach makes sure new projects get off the ground quickly -and achieve results faster.
The EU Framework Programme for Research and Innovation will be complemented by further measures to complete and further develop the European Research Area. These measures will aim at breaking down barriers to create a genuine single market for knowledge, research and innovation.
HEALTH GUIDELINES
WHO guidelines approved by the Guidelines Review Committee
The development of global guidelines ensuring the appropriate use of evidence represents one of the core functions of WHO. Recommendations that can impact upon health policies or clinical interventions are considered guidelines for WHO purposes. Below are some of the most recent guidelines.
NICE – National Institute for Health and Care Excellence
Lists of NICE guidance, including published guidance, in development and consultations
AHRQ – Agency for Healthcare Research and Quality
NGC – National Guidelines Clearinghouse is a public resource for evidence-based clinical practice guidelines.
Rehab 4 Alcoholism
Rehab 4 Alcoholism is a free and impartial helpline for people troubled with drug and alcohol issues. This aims to save lives by stopping addiction before it becomes too late. Tel: 0800 111 4108
EMA – European Medicines Agency Scientific Guidelines
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) prepares scientific guidelines in consultation with regulatory authorities in the European Union (EU) Member States, to help applicants prepare marketing-authorisation applications for human medicines. Guidelines provide a basis for practical harmonisation of how the EU Member States and the Agency interpret and apply the detailed requirements for the demonstration of quality, safety and efficacy that are in the Community directives.
DS MediGroup
The protagonists of innovation in Medicine and Health Share holding company, checks and attends companies in the area of IT Health Care. Coordinates the activity and supporting the operational companies in different areas as R & D, infrastructure, logistics and administrative, internal continuous educational process, new communication tools setup and deployment for the targeting activities and the community. The national and international research institutes and university clinics collaboration enables searches and developments of the technological innovation in the sanitary management and clinical medicine applications. The head office is located in Milano with branches in Rome and Naples.
Medical Devices and Safety
The role of medical devices is essential to the healthcare of EU citizens. The diversity and innovativeness of this sector contributes significantly to the enhancement of both the quality and efficacy of healthcare in the EU. Covering a wide range of products, from simple bandages to the most sophisticated life-support equipment, the medical devices sector plays a crucial role in the diagnosis, prevention, monitoring and treatment of diseases. It also helps improve the quality of life of those with disabilities. The medical devices sector helps save lives by providing innovative health care solutions regarding diagnosis, prevention and treatment. The sector has become increasingly important for the healthcare of EU citizens and an influencer on expenditure:
- The medical devices industry is a major employer in Europe, employing 575.000 people in the EU
- Total sales amount to €100 billion
- The sector represents some 25.000 companies, of which 95% are Small and Medium-sized Enterprises (SMEs)
The medical devices sector faces many challenges at national, European and international level, which may have an impact on their innovation capacity and overall competitiveness:
Public Health Systems: In particular, emerging needs such as developing a shared understanding of healthcare goals, overcoming health inequalities, an ageing society and exploiting the potential of e-health technologies
Finding the balance between patient s needs and financial sustainability: Ensuring that the sector can enhance better access for patients to devices whilst simultaneously ensuring that pricing and reimbursement policies are effective
Competitiveness and innovation: Challenges related to R&D, emerging technologies and the green economy, as well as issues related to the EU s trade and regulatory cooperation globally. SMEs in particular face challenges in this regard
President
Dr. Costigliola graduated in Medicine from the University of Naples in 1972 and with distinction, in Anesthesiology and Intensive Care from the University of Pisa in 1978. He also completed studies in Rheumatology, Dermatology, Procthology, Oncology, Surgery, Drugs Abuse, Emergency Treatment, Disaster Action, Hospital Organization, Medical Teaching Methodology and Computer and Audio-Visual Training for the Medical Profession.
He holds prominent positions in multiple prestigious organizations, including being the President of EPMA (European Predictive, Preventive, Personalized Medicine), the President of E.D.A. (European Depression Association), and the President of Medicinal Cannabis Europe since 2020. They serve on the Board of “The European Biotechnology Association” and are a Fellow of the World Certification Institute, where they also serve as a Councilor. Additionally, they are the President of the Oxford Union Academic Board of Directors and a member of the International Advisory Board at King Abdulaziz University in Saudi Arabia. He also a board member of CIRM in Rome (Centro Internazionale Radio Medico) and Councilor of WCI
His editorial experience includes serving on the board of the EPMA Journal (BMC/Springer), and With significant experience in clinical trials, European healthcare, and participation in EU projects (DG 22 and DG 5), he selected as an expert evaluator in the 5th Framework Programme. He possess extensive expertise in health informatics programs, teaching, and speaking at national and international conferences. He is proficient in Italian, French, English, Spanish, and Portuguese, and have been recognized with numerous honors, including being named Cavaliere Ufficiale and Commendatore of the Italian Republic, receiving the Diploma di benemerenza with “medaglia di la classe” from the Italian Red Cross, and being honored as Equitem Commendatorem Ordinis Sancti Gregorii Magni.
Board Members
Prof Manuel Pais Clemente
Dr Angelo Manenti
Dr Prisco Piscitelli
Prof Francesco Amenta
Prof Guglielmo Trovato
Prof Paolo Baron
Prof Luigi Gatta
Prof Sotirios Tsioumas
Prof Teresa Abbattista
Secretarial staff
Ms Jacqueline Rudolph
Mr Antonio Arcese
Dr Gopi Battineni
- All
- Corporate
- costigliola
- Directory
- EU
- From Members
- Jobs
- legal
- NEWS
- Non classé
- Partners
- PUBLICATIONS
- save the date
- Videos
- Back
- Professor of Human Histology
- Back
- Surgeon
- Dentist
- Reconstructive Surgery
- Non invasive Plastic Surgery
- Anesthesiology – Palliative care et Pain Management
- Cardiac surgery
- Cardiology
- Geriatry
- Ortho-Geriatric Medicine
- Gynecology
- Immunology-Serology
- Lifestyle Medicine
- Medical Ophthalmologist
- Medical Pharmacology
- Molecular diagnostics, pharmacogenetics and theragnostic.
- New therapies
- Obstetrics and Gynaecologist
- Occupational medecine
- ORL
- Pharmacogenetics and theragnostic
- Psychiatry
- Public health and medical research
- Regenerative medicine by non invasive non drug therapy
- General medicine
- Professors
- Professor of Human Histology
As the United States enters another period of transition in both federal and state governments, including the White House, Intealth™ reaffirms…
Manuale Di Primo soccorso : gestione delle emergenze mediche in mare per il diporto nautico prezentazione NICOLAS CARLONE Click here